Compare
ZyVersa Therapeutics, Inc. vs Bespoke Extracts, Inc. vs Polomar Health Services, Inc. vs Cell Source, Inc.
| Latest fiscal year | ZyVersa Therapeutics, Inc. ZVSA | Bespoke Extracts, Inc. BSPKLast annual report: year ended 2024-12-31 | Polomar Health Services, Inc. PMHS | Cell Source, Inc. CLCSLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 |
| Revenue | n/a | $1.12M | $648.2K | n/a |
| Revenue growth (YoY) | n/a | +42.3% | n/m | n/a |
| Gross margin | n/a | 40.5% | 71.0% | n/a |
| Operating margin | n/a | -89.0% | n/m | n/a |
| Net margin | n/a | -92.8% | n/m | n/a |
| Net income | -$24.95M | -$1.04M | -$10.70M | -$4.51M |
| EPS (Diluted) | -$4.18 | -$0.10 | -$0.39 | -$0.14 |
| Operating cash flow | -$5.11M | -$289.8K | -$396.0K | -$2.68M |
| Free cash flow | n/a | -$889.8K | n/a | n/a |
| Cash & equivalents | n/a | n/a | $132.2K | n/a |
| Total assets | $347.9K | $359.1K | $390.0K | $286.5K |
| Total liabilities | $12.73M | $2.45M | $1.61M | $18.82M |
| Shareholders' equity | -$12.39M | -$2.09M | -$1.22M | -$18.54M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 8.10M | 11.15M | 28.02M | 45.04M |
Revenue, most recent five fiscal years
| Fiscal year | ZyVersa Therapeutics, Inc. | Bespoke Extracts, Inc. | Polomar Health Services, Inc. | Cell Source, Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.12M Ended 2024-12-31 | $648.2K Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $785.5K Ended 2023-12-31 | $58.8K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $3.4K Ended 2022-12-31 | $41.8K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $34.5K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |